<DOC>
	<DOCNO>NCT02069535</DOCNO>
	<brief_summary>This trial open , national , multi-centre trial . The main objective trial ass tolerability up-dosing phase AVANZ® Cupressus arizonica measurement related Adverse Events .</brief_summary>
	<brief_title>An Open Trial Assess Tolerability AVANZ® Cupressus Immunotherapy</brief_title>
	<detailed_description>The main objective trial ass tolerability up-dosing phase AVANZ® Cupressus arizonica , measurement rate frequency patient investigational medicinal product ( IMP ) -related adverse event ( AEs ) primary endpoint .</detailed_description>
	<mesh_term>Conjunctivitis , Allergic</mesh_term>
	<criteria>A document clinically relevant history Cupressus arizonica pollen induce allergic rhinoconjunctivitis without asthma least one year prior trial entry . Positive Skin Prick Test ( SPT ) response Cupressus arizonica pollen ( wheal diameter ≥ 3 mm ) History severe asthma exacerbation emergency room visit admission asthma previous 12 month . Previous treatment immunotherapy Cupressus arizonica pollen extract within last 5 year ( initiation subcutaneous immunotherapy acceptable treatment discontinue reach maintenance dose ; SLIT 3 month last 5 year accept ) . Ongoing treatment allergenspecific immunotherapy product . A history anaphylaxis cardiorespiratory symptom ( immunotherapy , exerciseinduced , food allergy , drug idiopathic reaction ) . A systemic disease affect immune system ( e.g . insulindependent diabetes , autoimmune disease , immune complex disease , immune deficiency disease whether acquire ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>Cupressus arizonica</keyword>
</DOC>